201 related articles for article (PubMed ID: 26227479)
1. Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach.
Hagemann IS; O'Neill PK; Erill I; Pfeifer JD
Cancer Genet; 2015 Sep; 208(9):441-7. PubMed ID: 26227479
[TBL] [Abstract][Full Text] [Related]
2. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
[TBL] [Abstract][Full Text] [Related]
3. Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.
Carter J; Tseng LH; Zheng G; Dudley J; Illei P; Gocke CD; Eshleman JR; Lin MT
Am J Clin Pathol; 2015 Oct; 144(4):620-8. PubMed ID: 26386083
[TBL] [Abstract][Full Text] [Related]
4. Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy.
Hagemann IS; Cottrell CE; Lockwood CM
Cancer Genet; 2013 Dec; 206(12):420-31. PubMed ID: 24388712
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of amplicon-based next-generation sequencing in cancer.
Chang F; Li MM
Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
[TBL] [Abstract][Full Text] [Related]
6. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients.
Malapelle U; Vigliar E; Sgariglia R; Bellevicine C; Colarossi L; Vitale D; Pallante P; Troncone G
J Clin Pathol; 2015 Jan; 68(1):64-8. PubMed ID: 25378536
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical validation of a next generation sequencing testing panel.
Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
[TBL] [Abstract][Full Text] [Related]
9. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
10. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
11. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
12. Performance evaluation of the next-generation sequencing approach for molecular diagnosis of hereditary hearing loss.
Sivakumaran TA; Husami A; Kissell D; Zhang W; Keddache M; Black AP; Tinkle BT; Greinwald JH; Zhang K
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1007-16. PubMed ID: 23525850
[TBL] [Abstract][Full Text] [Related]
13. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Takenaka M; Saito M; Iwakawa R; Yanaihara N; Saito M; Kato M; Ichikawa H; Shibata T; Yokota J; Okamoto A; Kohno T
Int J Oncol; 2015; 46(6):2389-98. PubMed ID: 25846456
[TBL] [Abstract][Full Text] [Related]
14. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology.
Le Mercier M; D'Haene N; De Nève N; Blanchard O; Degand C; Rorive S; Salmon I
Histopathology; 2015 Jan; 66(2):215-24. PubMed ID: 24834793
[TBL] [Abstract][Full Text] [Related]
16. Clinical Applications of Next-Generation Sequencing in Cancer Diagnosis.
Sabour L; Sabour M; Ghorbian S
Pathol Oncol Res; 2017 Apr; 23(2):225-234. PubMed ID: 27722982
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting the success of next-generation sequencing in cytology specimens.
Roy-Chowdhuri S; Goswami RS; Chen H; Patel KP; Routbort MJ; Singh RR; Broaddus RR; Barkoh BA; Manekia J; Yao H; Medeiros LJ; Staerkel G; Luthra R; Stewart J
Cancer Cytopathol; 2015 Nov; 123(11):659-68. PubMed ID: 26230354
[TBL] [Abstract][Full Text] [Related]
18. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics.
Sikkema-Raddatz B; Johansson LF; de Boer EN; Almomani R; Boven LG; van den Berg MP; van Spaendonck-Zwarts KY; van Tintelen JP; Sijmons RH; Jongbloed JD; Sinke RJ
Hum Mutat; 2013 Jul; 34(7):1035-42. PubMed ID: 23568810
[TBL] [Abstract][Full Text] [Related]
19. mirTrios: an integrated pipeline for detection of de novo and rare inherited mutations from trios-based next-generation sequencing.
Li J; Jiang Y; Wang T; Chen H; Xie Q; Shao Q; Ran X; Xia K; Sun ZS; Wu J
J Med Genet; 2015 Apr; 52(4):275-81. PubMed ID: 25596308
[TBL] [Abstract][Full Text] [Related]
20. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
